Department of Dermatology, Hospital Arnau de Vilanova, Valencia, Spain.
Dermatol Ther. 2013 May-Jun;26(3):257-9. doi: 10.1111/j.1529-8019.2013.01549.x.
Omalizumab is a monoclonal anti-IgE antibody approved for the treatment of severe allergic asthma. There is increasing evidence in the literature of its usefulness in chronic urticaria. Herein, we report a retrospective case series of 15 patients with chronic idiopathic urticaria treated with omalizumab. We reviewed their medical records to assess the improvement achieved after 3 and 6 months of treatment. Complete response was defined as symptom disappearance that could be followed by discontinuation of antihistamines, and partial response as symptom improvement, but with symptom worsening when attempting to discontinue antihistamines. After 3 months of treatment, 12 patients responded, with partial response in 9 and complete response in 3. At 6 months, 8 of 10 patients continuing on omalizumab had a complete response and 2 a partial response. The results of the present retrospective series show the effectiveness of omalizumab in most treated patients, which is consistent with other recently published series and studies. These data support its role in the management of patients with chronic urticaria refractory to conventional treatments.
奥马珠单抗是一种单克隆抗 IgE 抗体，已被批准用于治疗严重的过敏性哮喘。越来越多的文献证据表明，它对慢性荨麻疹也有用。在此，我们报告了 15 例慢性特发性荨麻疹患者接受奥马珠单抗治疗的回顾性病例系列。我们回顾了他们的病历，以评估治疗 3 个月和 6 个月后的改善情况。完全缓解定义为症状消失，可停用抗组胺药；部分缓解定义为症状改善，但当试图停用抗组胺药时症状恶化。治疗 3 个月后，12 例患者有反应，其中 9 例部分缓解，3 例完全缓解。在 6 个月时，10 例继续接受奥马珠单抗治疗的患者中，8 例完全缓解，2 例部分缓解。本回顾性系列研究的结果表明，奥马珠单抗对大多数接受治疗的患者有效，这与其他最近发表的系列研究结果一致。这些数据支持其在治疗对常规治疗反应不佳的慢性荨麻疹患者中的作用。
